The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NR9NT     (3R,5R)-7-[4-(4- fluorophenyl)-5...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of cerivastatin


Psychiatry related information on cerivastatin

  • However, cerivastatin improves endothelial dysfunction, possesses anti-inflammatory, antioxidant, anticoagulant, antithrombotic, antiproliferative, plaque-stabilizing, immunmodulatory, and angiogenic effects, and may even prevent tumor growth, Alzheimer's disease, and osteoporosis [5].

High impact information on cerivastatin


Chemical compound and disease context of cerivastatin


Biological context of cerivastatin


Anatomical context of cerivastatin


Associations of cerivastatin with other chemical compounds


Gene context of cerivastatin


Analytical, diagnostic and therapeutic context of cerivastatin

  • In a double-blind, placebo-controlled, randomized crossover study, 15 stable mild hyperglycemic patients without treatment and with features of metabolic syndrome were treated with cerivastatin (0.4 mg/day) or placebo for 3 months [26].
  • At 1.0 mg/kg, cerivastatin inhibited the diabetes-induced expansion of mesangial and tuft areas on histological examination of the kidneys, as well as the loss of anionic sites from the GBM evaluated with polyetyleneimine and the intraglomerular infiltration of ED1-positive macrophages evaluated by immunohistochemistry [9].
  • Cyclosporine steady-state concentration-time profiles were determined in blood with monoclonal (EMIT [enzyme multiplied immunoassay technique] assay, parent drug specific) and polyclonal antibodies (FPIA [fluorescence polarization immunoassay] assay, cyclosporine plus metabolites) during cerivastatin cotreatment and compared with predosing data [20].
  • The overall incidence and nature of adverse events reported with cerivastatin in clinical trials was similar to that of placebo [11].
  • METHODS: The effects of cerivastatin on skeletal reconstruction by vascularized bone allograft were investigated in a rat tibia-fibula graft model [27].


  1. Pharmacological interactions of statins. Paoletti, R., Corsini, A., Bellosta, S. Atherosclerosis. Supplements. (2002) [Pubmed]
  2. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Aikawa, M., Rabkin, E., Sugiyama, S., Voglic, S.J., Fukumoto, Y., Furukawa, Y., Shiomi, M., Schoen, F.J., Libby, P. Circulation (2001) [Pubmed]
  3. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Fromigu??, O., Ha??, E., Modrowski, D., Bouvet, S., Jacquel, A., Auberger, P., Marie, P.J. Cell Death Differ. (2006) [Pubmed]
  4. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. John, S., Delles, C., Jacobi, J., Schlaich, M.P., Schneider, M., Schmitz, G., Schmieder, R.E. J. Am. Coll. Cardiol. (2001) [Pubmed]
  5. Cerivastatin: a cellular and molecular drug for the future? Siegel-Axel, D.I. Cell. Mol. Life Sci. (2003) [Pubmed]
  6. Statin-associated myopathy. Thompson, P.D., Clarkson, P., Karas, R.H. JAMA (2003) [Pubmed]
  7. Cerivastatin-induced rhabdomyolysis. Rodríguez, M.L., Mora, C., Navarro, J.F. Ann. Intern. Med. (2000) [Pubmed]
  8. Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable? Tomlinson, B., Lan, I.W. Am. J. Med. (2001) [Pubmed]
  9. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Ota, T., Takamura, T., Ando, H., Nohara, E., Yamashita, H., Kobayashi, K. Diabetologia (2003) [Pubmed]
  10. Toxicity of statins on rat skeletal muscle mitochondria. Kaufmann, P., T??r??k, M., Zahno, A., Waldhauser, K.M., Brecht, K., Kr??henb??hl, S. Cell. Mol. Life Sci. (2006) [Pubmed]
  11. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. Plosker, G.L., Dunn, C.I., Figgitt, D.P. Drugs (2000) [Pubmed]
  12. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. Yang, Z., Kozai, T., van der Loo, B., Viswambharan, H., Lachat, M., Turina, M.I., Malinski, T., Lüscher, T.F., van de Loo, B. J. Am. Coll. Cardiol. (2000) [Pubmed]
  13. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. Staal, A., Frith, J.C., French, M.H., Swartz, J., Güngör, T., Harrity, T.W., Tamasi, J., Rogers, M.J., Feyen, J.H. J. Bone Miner. Res. (2003) [Pubmed]
  14. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. Zoja, C., Corna, D., Camozzi, D., Cattaneo, D., Rottoli, D., Batani, C., Zanchi, C., Abbate, M., Remuzzi, G. J. Am. Soc. Nephrol. (2002) [Pubmed]
  15. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. Nahrendorf, M., Hu, K., Hiller, K.H., Galuppo, P., Fraccarollo, D., Schweizer, G., Haase, A., Ertl, G., Bauer, W.R., Bauersachs, J. J. Am. Coll. Cardiol. (2002) [Pubmed]
  16. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Wong, W.W., Tan, M.M., Xia, Z., Dimitroulakos, J., Minden, M.D., Penn, L.Z. Clin. Cancer Res. (2001) [Pubmed]
  17. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis. Ganné, F., Vasse, M., Beaudeux, J.L., Peynet, J., François, A., Mishal, Z., Chartier, A., Tobelem, G., Vannier, J.P., Soria, J., Soria, C. Thromb. Haemost. (2000) [Pubmed]
  18. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Hattori, Y., Nakanishi, N., Kasai, K. Cardiovasc. Res. (2002) [Pubmed]
  19. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Backman, J.T., Kyrklund, C., Neuvonen, M., Neuvonen, P.J. Clin. Pharmacol. Ther. (2002) [Pubmed]
  20. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Mück, W., Mai, I., Fritsche, L., Ochmann, K., Rohde, G., Unger, S., Johne, A., Bauer, S., Budde, K., Roots, I., Neumayer, H.H., Kuhlmann, J. Clin. Pharmacol. Ther. (1999) [Pubmed]
  21. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Mazzu, A.L., Lasseter, K.C., Shamblen, E.C., Agarwal, V., Lettieri, J., Sundaresen, P. Clin. Pharmacol. Ther. (2000) [Pubmed]
  22. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Sebestjen, M., Keber, I., Zegura, B., Simcic, S., Bozic, M., Fressart, M.M., Stegnar, M. Thromb. Haemost. (2004) [Pubmed]
  23. Mechanistic studies on metabolic interactions between gemfibrozil and statins. Prueksaritanont, T., Zhao, J.J., Ma, B., Roadcap, B.A., Tang, C., Qiu, Y., Liu, L., Lin, J.H., Pearson, P.G., Baillie, T.A. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  24. The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor. Lawler, O.A., Miggin, S.M., Kinsella, B.T. Br. J. Pharmacol. (2001) [Pubmed]
  25. Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Kobayashi, K., Yamanaka, Y., Iwazaki, N., Nakajo, I., Hosokawa, M., Negishi, M., Chiba, K. Drug Metab. Dispos. (2005) [Pubmed]
  26. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Paniagua, J.A., López-Miranda, J., Escribano, A., Berral, F.J., Marín, C., Bravo, D., Paz-Rojas, E., Gómez, P., Barcos, M., Moreno, J.A., Pérez-Jiménez, F. Diabetes (2002) [Pubmed]
  27. Skeletal reconstruction by vascularized allogenic bone transplantation: effects of statin in rats. Ohno, T., Shigetomi, M., Ihara, K., Matsunaga, T., Hashimoto, T., Kawano, H., Sugiyama, T., Kawai, S. Transplantation (2003) [Pubmed]
WikiGenes - Universities